- Home
- NAT vs PHAT Comparison
NAT vs PHAT Comparison
Compare NAT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAT | PHAT |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.8M | 894.0M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NAT | PHAT |
|---|---|---|
| Price | $5.84 | $12.59 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.00 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 3.8M | 1.3M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 8.50% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $77.72 | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $525.49 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $2.55 | $3.69 |
| 52 Week High | $6.34 | $18.31 |
Technical Indicators
Market Signals| Indicator | NAT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 54.22 |
| Support Level | $5.39 | $10.25 |
| Resistance Level | $6.30 | $13.03 |
| Average True Range (ATR) | 0.20 | 0.93 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 74.31 | 88.36 |
Price Performance
Historical ComparisonAbout NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.